Autoinflammatory Syndromes

Pediatric Clinics of North America

Volumn 59, Issue 2, 2012, Pages 447-470

  Hashkes, Philip J ^a,b   Toker, Ori ^c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Autoinflammatory syndromes; Interleukin 1; Periodic fever

Indexed keywords

ANTIHISTAMINIC AGENT; AZITHROMYCIN; CANAKINUMAB; CIMETIDINE; COLCHICINE; COLCYRS; CORTICOSTEROID; CYCLOSPORIN; DAPSONE; ETANERCEPT; ETRETIN; INFLIXIMAB; INTERFERON; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SALAZOSULFAPYRIDINE; SIMVASTATIN; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AMYLOIDOSIS; AUTOINFLAMMATORY DISEASE; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW SUPPRESSION; CERVICAL LYMPHADENOPATHY; CHRONIC OSTEOMYELITIS; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; CLINICAL FEATURE; CONJUNCTIVITIS; DEFICIENCY OF THE INTERLEUKIN 1 RECEPTOR ANTAGONIST; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; EPISCLERITIS; ERYSIPELAS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL GENERALIZED PUSTULAR PSORIASIS; FAMILIAL MEDITERRANEAN FEVER; FEVER; GENE; GENE MUTATION; HEADACHE; HEARING LOSS; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATION; INNATE IMMUNITY; MENINGITIS; MENTAL DEFICIENCY; MONARTHRITIS; MUCKLE WELLS SYNDROME; MYALGIA; MYOSITIS; NALP12 GENE; PAPA SYNDROME; PAPILLITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PFAPA SYNDROME; PREVALENCE; PUSTULAR PSORIASIS; RECURRENT FEVER; REVIEW; SINGLE DRUG DOSE; SPLENOMEGALY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; UVEITIS;

ANTI-INFLAMMATORY AGENTS; CHILD; COLCHICINE; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FAMILIAL MEDITERRANEAN FEVER; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MEVALONATE KINASE DEFICIENCY; OSTEOMYELITIS; RECEPTORS, INTERLEUKIN-1 TYPE I; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84860516763     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.03.005     Document Type: Review

References (83)

1. McGonagle D., Aziz A., Dickie L.J., et al. An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 2009, 65:38R-45R.
2. Padeh S. Periodic fever syndromes. Pediatr Clin North Am 2005, 52:577-609.
3. Gattorno M., Sormani M.P., D'Osualdo A., et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008, 58:1823-1832.
4. Masters S.L., Simon A., Aksentijevich I., et al. Horror Autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668.
5. Siegal S. Benign paroxysmal peritonitis. Ann Intern Med 1945, 22:1-21.
6. Ben-Chetrit E., Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009, 61:1447-1453.
7. Pras E., Aksentijevich I., Gruberg L., et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med 1992, 291:932-944.
8. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 1997, 90:797-807.
9. The French FMF Consortium A candidate gene for familial Mediterranean fever. Nat Genet 1997, 17:25-31.
10. Gershoni-Baruch R., Brik R., Zacks N., et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003, 48:1149-1155.
11. Tchernitchko D., Moutereau S., Legrendre M., et al. MEFV analysis is of particularly weak diagnostic value for recurrent fevers in Western European Caucasian patients. Arthritis Rheum 2005, 52:3603-3605.
12. Infevers. Available at: . Accessed September 21, 2011. http://fmf.igh.cnrs.fr/ISSAID/infevers/.
13. Chae J.J., Wood G., Masters S.L., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103:9982-9987.
14. Samuels J., Aksenitjevich I., Yelizaveta T., et al. Familial Mediterranean fever at the millennium: clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998, 77:268-297.
15. Padeh S., Livneh A., Pras E., et al. Familial Mediterranean fever in children presenting with attacks of fever alone. J Rheumatol 2010, 37:865-869.
16. Touitou I., Sarkisian T., Medlej-Hashim M., et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
17. Hawkins P.N., Lavender J.P., Pepys M.B. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990, 323:508-513.
18. Livneh A., Langevitz P., Zemer D., et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997, 40:1879-1885.
19. Yalçinkaya F., Ozen S., Ozçakar Z.B., et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009, 48:395-398.
20. Berkun Y., Padeh S., Reichman B., et al. A single testing of serum amyloid A levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. Semin Arthritis Rheum 2007, 37:182-188.
21. Goldfinger S.E. Colchicine for familial Mediterranean fever. N Engl J Med 1972, 287:1302.
22. Zemer D., Revach M., Pras M., et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974, 291:932-934.
23. Zemer D., Pras M., Sohar E., et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986, 314:1001-1005.
24. Lidar M., Scherrmann J.M., Shinar Y., et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004, 33:273-282.
25. Kallinich T., Haffner D., Nichues T., et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007, 119:e474-e483.
26. Ben-Chetrit E., Ben-Chetrit A., Berkun Y., et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified?. Arthritis Care Res (Hoboken) 2010, 62:143-148.
27. Meinzer U., Quartier P., Alexandra J.F., et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011, 41(2):265-271.
28. Ozen S., Bilginer Y., Aktay Ayaz N., et al. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011, 38:516-518.
29. Hashkes P.J., Spalding S.J., Giannini E.H., et al. Rilonacept (interleukin-1 trap) for treatment of colchicine resistant familial Mediterranean fever: a randomized, multicenter double-blinded, alternating treatment phase II trial. Arthritis Rheum 2011, 63(Suppl). S952.
30. van der Meer J.W., Vossen J.M., Radl J., et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984, 1:1087-1090.
31. Houton S.M., Kuis W., Duran M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999, 22:175-177.
32. Drenth J.P., Cuisset L., Grateau G., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. Nat Genet 1999, 22:178-181.
33. Houten S.M., Frenkel J., Rijkers G.T., et al. Temperature dependence of mutant mevalonate kinase activity as pathogenic factor in hyper-IgD and periodic fever syndrome. Hum Mol Genet 2002, 11:3115-3124.
34. Frenkel J., Rijkers G.T., Mandey S.H., et al. Lack of isoprenoid products raises ex vivo interleukin-1 beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002, 46:2794-2803.
35. Simon A., International HIDS Study Group Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008, 87:301-310.
36. Aksentijevich I., Masters S.L., Ferguson P.J., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009, 360:2426-2437.
37. Reddy S., Jia S., Geoffrey R., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009, 360:2438-2444.
38. Marrakchi S., Guigue P., Renshaw B.R., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011, 365:620-628.
39. Onoufriadis A., Simpson M.A., Pink A.E., et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet 2011, 89:432-437.
40. Viguier M., Guigue P., Pagès C., et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010, 153:66-67.
41. Williamson L.M., Hull D., Mehta R., et al. Familial Hibernian fever. Q J Med 1982, 51:469-480.
42. McDermott M.F., Aksentijevich I., Galon J., et al. Germline mutation in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
43. Aganna E., Hammond L., Hawkins P., et al. Heterogeneity among patients with tumor necrosis factor-associated periodic syndrome phenotypes. Arthritis Rheum 2003, 48:2632-2644.
44. Pelagatti M.A., Meini A., Caorsi R., et al. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 2011, 63:1141-1150.
45. Arkwright P.D., McDermott M.F., Houton S.M., et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 2002, 130:484-488.
46. Bulua A.C., Simon A., Maddipati R., et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011, 208:519-533.
47. Gattorno M., Pelagatti M.A., Meini A., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008, 58:1516-1520.
48. Vaitla P.M., Radford P.M., Tighe P.J., et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011, 63:1151-1155.
49. Hoffman H., Mueller J., Brodie D., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
50. Feldmann J., Prieur A.M., Quartier P., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71:198-203.
51. Aksentijevich I., Putnam C.D., Remmers E.F., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
52. Tanaka N., Izawa K., Saito M.K., et al. High incidence of NLRP3 somatic mosaicism in chronic infantile neurological cutaneous and articular syndrome patients: the results of an international multicenter collaborative study. Arthritis Rheum 2011, 63:3625-3632.
53. Gattorno M., Tassi S., Carta S., et al. Pattern of IL-1β secretion on response to lipopolysaccharide and ATP before and after IL-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007, 56:3138-3148.
54. Hoffman H.M., Throne M.L., Amar N.J., et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes. Arthritis Rheum 2008, 58:2443-2445.
55. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Canakinumab in CAPS Study Group, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
56. Neven B., Marvillet I., Terrada C., et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010, 62:258-267.
57. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2093-2102.
58. Aksentijevich I., Nowak M., Mallah M., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46:3340-3348.
59. Goldbach-Mansky R., Dailey N.J., Canna S.W., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006, 355:581-592.
60. Jeru I., Duquesnoy P., Fernandes-Alnemri T., et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci U S A 2008, 105:1614-1619.
61. Borghini S., Tassi S., Chiesa S., et al. Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis Rheum 2011, 63:830-839.
62. Jéru I., Hentgen V., Normand S., et al. Role of interleukin-1β in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy. Arthritis Rheum 2011, 63:2142-2148.
63. Lindor N.M., Arsenault T.M., Solomon H., et al. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum and acne: PAPA syndrome. Mayo Clin Proc 1997, 72:611-615.
64. Wise C.A., Gillum J.D., Seidman C.E., et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002, 11:961-969.
65. Shoham N.G., Centola M., Mansfield E., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA as disorders in the same pathway. Proc Natl Acad Sci U S A 2003, 100:13501-13506.
66. Marshall G.S., Edwards K.M., Butler J., et al. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr 1987, 110:43-46.
67. Stojanov S., Lapidus S., Chitkara P., et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc Natl Acad Sci U S A 2011, 108:7148-7153.
68. Padeh S., Brezniak N., Zemer D., et al. Periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome: clinical characteristics and outcome. J Pediatr 1999, 135:98-101.
69. Berkun Y., Levy R., Hurwitz A., et al. The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum 2011, 40:467-472.
70. Tasher D., Somekh E., Dalal I. PFAPA syndrome: new clinical aspects revealed. Arch Dis Child 2006, 91:981-984.
71. Thomas K.T., Feder H.M., Lawton A.R., et al. Periodic fever syndrome in children. J Pediatr 1999, 135:15-21.
72. Gattorno M., Caorsi R., Meini A., et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009, 124:e721-e728.
73. Feder H.M. Cimetidine treatment for periodic fever associated with aphthous stomatitis, pharyngitis and cervical adenitis. Pediatr Infect Dis J 1992, 11:318-321.
74. Garavello W., Pignataro L., Gaini L., et al. Tonsillectomy in children with periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr 2011, 159(1):138-142.
75. Wurster V.M., Carlucci J.G., Feder H.M., et al. Long-term follow-up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. J Pediatr 2011, 159:958-964.
76. Giedion A., Holthusen W., Masel L.F., et al. Subacute and chronic " symmetrical" osteomyelitis. Ann Radiol 1972, 15:329-342.
77. Laxer R.M., Shore A.D., Manson D., et al. Chronic recurrent multifocal osteomyelitis and psoriasis: a report of a new association and review of related disorders. Semin Arthritis Rheum 1988, 17:260-270.
78. Twilt M., Laxer R.M. Clinical care of children with sterile bone inflammation. Curr Opin Rheumatol 2011, 23:424-431.
79. John C., Gilsdorf J. Recurrent fever in children. Pediatr Infect Dis J 2002, 21:1071-1077.
80. Long S.S. Distinguishing among prolonged, recurrent, and periodic fever syndromes: approach of a pediatric infectious diseases subspecialist. Pediatr Clin North Am 2005, 52:811-835.
81. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology 2004, 43:410-415.
82. Federici L., Rittore-Domingo C., Kone-Paut I., et al. A decision tree for genetic diagnosis of hereditary periodic fevers in unselected patients. Ann Rheum Dis 2006, 65:1427-1432.
83. Simon A., van der Meer J.W., Vesely R., et al. Approach to genetic analysis in the diagnosis of hereditary autoinflammatory syndromes. Rheumatology (Oxford) 2006, 45:269-273.